Literature DB >> 20134486

Primary sclerosing cholangitis: what is the role of ursodeoxycholic acid in therapy for PSC?

Roger W Chapman.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20134486     DOI： 10.1038/nrgastro.2009.235

Source DB:  PubMed          Journal:  Nat Rev Gastroenterol Hepatol        ISSN： 1759-5045            Impact factor:   46.802


× No keyword cloud information.
  10 in total

1.  High-dose ursodeoxycholic acid as a therapy for patients with primary sclerosing cholangitis.

Authors:  D M Harnois; P Angulo; R A Jorgensen; N F Larusso; K D Lindor
Journal:  Am J Gastroenterol       Date:  2001-05       Impact factor: 10.864

2.  Ursodiol for primary sclerosing cholangitis. Mayo Primary Sclerosing Cholangitis-Ursodeoxycholic Acid Study Group.

Authors:  K D Lindor
Journal:  N Engl J Med       Date:  1997-03-06       Impact factor: 91.245

3.  High-dose ursodeoxycholic acid in primary sclerosing cholangitis: a 5-year multicenter, randomized, controlled study.

Authors:  Rolf Olsson; Kirsten M Boberg; Ove Schaffalitsky de Muckadell; Stefan Lindgren; Rolf Hultcrantz; Geir Folvik; Helge Bell; Magnhild Gangsøy-Kristiansen; Jon Matre; Andreas Rydning; Ola Wikman; Ake Danielsson; Hanna Sandberg-Gertzén; Kjell-Arne Ung; Anders Eriksson; Lars Lööf; Hanne Prytz; Hanns-Ulrich Marschall; Ulrika Broomé
Journal:  Gastroenterology       Date:  2005-11       Impact factor: 22.682

4.  High-dose ursodeoxycholic acid in the treatment of primary sclerosing cholangitis: throwing the urso out with the bathwater?

Authors:  Roger W Chapman
Journal:  Hepatology       Date:  2009-09       Impact factor: 17.425

5.  Ursodeoxycholic acid aggravates bile infarcts in bile duct-ligated and Mdr2 knockout mice via disruption of cholangioles.

Authors:  Peter Fickert; Gernot Zollner; Andrea Fuchsbichler; Conny Stumptner; Andreas H Weiglein; Frank Lammert; Hanns-Ulrich Marschall; Oleksiy Tsybrovskyy; Kurt Zatloukal; Helmut Denk; Michael Trauner
Journal:  Gastroenterology       Date:  2002-10       Impact factor: 22.682

Review 6.  An update on primary sclerosing cholangitis.

Authors:  James Rl Maggs; Roger W Chapman
Journal:  Curr Opin Gastroenterol       Date:  2008-05       Impact factor: 3.287

7.  Side chain structure determines unique physiologic and therapeutic properties of norursodeoxycholic acid in Mdr2-/- mice.

Authors:  Emina Halilbasic; Romina Fiorotto; Peter Fickert; Hanns-Ulrich Marschall; Tarek Moustafa; Carlo Spirli; Andrea Fuchsbichler; Judith Gumhold; Dagmar Silbert; Kurt Zatloukal; Cord Langner; Uday Maitra; Helmut Denk; Alan F Hofmann; Mario Strazzabosco; Michael Trauner
Journal:  Hepatology       Date:  2009-06       Impact factor: 17.425

8.  High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis.

Authors:  Keith D Lindor; Kris V Kowdley; Velimir A C Luketic; M Edwyn Harrison; Timothy McCashland; Alex S Befeler; Denise Harnois; Roberta Jorgensen; Jan Petz; Jill Keach; Jody Mooney; Carol Sargeant; Julie Braaten; Tamara Bernard; Debra King; Ellen Miceli; Jeff Schmoll; Tanya Hoskin; Prabin Thapa; Felicity Enders
Journal:  Hepatology       Date:  2009-09       Impact factor: 17.425

9.  High dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis is safe and effective.

Authors:  Susan N Cullen; Christian Rust; Kenneth Fleming; Cathryn Edwards; Ulrich Beuers; Roger W Chapman
Journal:  J Hepatol       Date:  2008-02-14       Impact factor: 25.083

10.  A novel role for ursodeoxycholic acid in inhibiting apoptosis by modulating mitochondrial membrane perturbation.

Authors:  C M Rodrigues; G Fan; X Ma; B T Kren; C J Steer
Journal:  J Clin Invest       Date:  1998-06-15       Impact factor: 14.808
  10 in total
  2 in total

Review 1.  Molecular mechanisms of ursodeoxycholic acid toxicity & side effects: ursodeoxycholic acid freezes regeneration & induces hibernation mode.

Authors:  Magd A Kotb
Journal:  Int J Mol Sci       Date:  2012-07-17       Impact factor: 6.208

2.  The Nonsteroidal Farnesoid X Receptor Agonist Cilofexor (GS-9674) Improves Markers of Cholestasis and Liver Injury in Patients With Primary Sclerosing Cholangitis.

Authors:  Michael Trauner; Aliya Gulamhusein; Bilal Hameed; Stephen Caldwell; Mitchell L Shiffman; Charles Landis; Bertus Eksteen; Kosh Agarwal; Andrew Muir; Simon Rushbrook; Xiaomin Lu; Jun Xu; Jen-Chieh Chuang; Andrew N Billin; Georgia Li; Chuhan Chung; G Mani Subramanian; Robert P Myers; Christopher L Bowlus; Kris V Kowdley
Journal:  Hepatology       Date:  2019-03-10       Impact factor: 17.425
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.